<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee18038b95a">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
  <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
</role>
 <role>
  <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
  <roleTerm authority="marcrelator" type="code">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Government Accountability Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">author</roleTerm>
  <roleTerm authority="marcrelator" type="code">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<extension>
 <collectionCode>GAOREPORTS</collectionCode>
 <category>Legislative Agency Publications</category>
 <waisDatabaseName>gao</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2010-08-12</dateIngested>
</extension>
<originInfo>
 <publisher>U.S. Government Printing Office</publisher>
 <dateIssued encoding="w3cdtf">2007-06-25</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
 <extent>15 p.</extent>
</physicalDescription>
<classification authority="sudocs">GA 1.13:GAO-07-882R</classification>
<identifier type="uri">https://www.govinfo.gov/app/details/GAOREPORTS-GAO-07-882R</identifier>
<identifier type="local">P0b002ee18038b95a</identifier>
<identifier type="former package identifier">f:d07882r</identifier>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2010-08-12</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2011-03-24</recordChangeDate>
 <recordIdentifier source="DGPO">GAOREPORTS-GAO-07-882R</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<extension>
 <docClass>REPORT</docClass>
 <accessId>GAOREPORTS-GAO-07-882R</accessId>
 <reportNumber>GAO-07-882R</reportNumber>
 <subject>Cost analysis</subject>
 <subject>Financial statement audits</subject>
 <subject>Financial statements</subject>
 <subject>Medical equipment</subject>
 <subject>Medical technology</subject>
 <subject>Regulatory agencies</subject>
 <subject>Reporting requirements</subject>
 <subject>User fees</subject>
 <subject>Medical devices</subject>
 <type>Correspondence</type>
 <accountNo>A71327</accountNo>
 <statuteAtLarge volume="116">
                      <pages pages="1588"></pages>
                </statuteAtLarge>
 <statuteAtLarge volume="119">
                      <pages pages="439"></pages>
                </statuteAtLarge>
</extension>
<titleInfo>
 <title>Food and Drug Administration: Methodologies for Identifying and Allocating Costs of Reviewing Medical Device Applications Are Consistent with Federal Cost Accounting Standards, and Staffing Levels for Reviews Have Generally Increased in Recent Years</title>
</titleInfo>
<abstract>The Food and Drug Administration (FDA) is the agency responsible
for ensuring the safety and effectiveness of medical		 
devices--such as catheters and artificial hearts--marketed in the
United States. As part of its regulatory responsibilities, FDA	 
reviews applications submitted by medical device companies for	 
devices they wish to market, including devices that are new or	 
those that include modifications to already approved devices. The
Medical Device User Fee and Modernization Act of 2002 (MDUFMA)	 
authorized FDA, beginning in fiscal year 2003, to charge user	 
fees for various types of device applications. User fees were	 
intended to provide resources to FDA, to increase staffing for	 
medical device reviews and speed the timeliness of reviews, in	 
addition to resources otherwise provided through the annual	 
appropriations process. Under MDUFMA, FDA is required to report  
to the congressional committees of jurisdiction annually on the  
implementation of the user fee program. FDA submitted financial  
reports that include information such as amounts collected from  
user fees, the costs of reviewing device applications, and	 
staffing levels FDA dedicated to the review of medical device	 
applications for each fiscal year from 2003 through 2005. In	 
response to industry concerns about the need for more cost	 
information, FDA supplemented these MDUFMA financial reports by  
reporting more detailed information on the estimated average cost
of reviewing medical device applications in those 3 years.	 
Industry has challenged the appropriateness of the methodologies 
FDA used to identify the total cost of the process for reviewing 
medical device applications and the average costs of reviewing	 
various types of applications. Industry has also questioned the  
degree to which staffing of the device review process has	 
increased since the enactment of MDUFMA. MDUFMA will expire on	 
October 1, 2007, and Congress is currently deliberating its	 
reauthorization. You asked us to review FDA&apos;s methodology for	 
determining costs of the process of reviewing device		 
applications, as well as changes in the staff levels dedicated to
that process since MDUFMA was implemented. In this report, we	 
evaluate (1) whether FDA&apos;s methodologies for identifying its	 
annual costs of reviewing device applications and its method for 
allocating these costs among various application types are	 
consistent with federal cost accounting standards, and (2) the	 
extent to which staffing levels for the process of reviewing	 
device applications have changed since fiscal year 2002, the	 
baseline year before MDUFMA went into effect, and how these	 
changes in staffing levels have been distributed within FDA.</abstract>
<location>
 <url displayLabel="HTML rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-07-882R/html/GAOREPORTS-GAO-07-882R.htm</url>
 <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-07-882R/pdf/GAOREPORTS-GAO-07-882R.pdf</url>
</location>
<identifier type="preferred citation">GAO-07-882R</identifier>
<location>
 <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/GAOREPORTS-GAO-07-882R</url>
</location>
<note>Correspondence</note>
<extension>
 <searchTitle>GAO-07-882R; Food and Drug Administration: Methodologies for Identifying and Allocating Costs of Reviewing Medical Device Applications Are Consistent with Federal Cost Accounting Standards, and Staffing Levels for Reviews Have Generally Increased in Recent Years;
            </searchTitle>
</extension>
<subject>
 <topic>Cost analysis</topic>
 <topic>Financial statement audits</topic>
 <topic>Financial statements</topic>
 <topic>Medical equipment</topic>
 <topic>Medical technology</topic>
 <topic>Regulatory agencies</topic>
 <topic>Reporting requirements</topic>
 <topic>User fees</topic>
 <topic>Medical devices</topic>
</subject>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Statutes at Large</title>
  <partNumber>Volume 116 Page 1588</partNumber>
</titleInfo>
 <identifier type="Statute citation">116 Stat. 1588</identifier>
</relatedItem>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Statutes at Large</title>
  <partNumber>Volume 119 Page 439</partNumber>
</titleInfo>
 <identifier type="Statute citation">119 Stat. 439</identifier>
</relatedItem>
</mods>